On Tuesday, ARS Pharmaceuticals Inc (NASDAQ: SPRY) opened higher 1.88% from the last session, before settling in for the closing price of $11.20. Price fluctuations for SPRY have ranged from $5.18 to $18.51 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -34.76%. Company’s average yearly earnings per share was noted -2.19% at the time writing. With a float of $51.12 million, this company’s outstanding shares have now reached $97.15 million.
Considering the fact that the conglomerate employs 26 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 93.97%, operating margin of -2384.0%, and the pretax margin is -1934.75%.
ARS Pharmaceuticals Inc (SPRY) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ARS Pharmaceuticals Inc is 47.40%, while institutional ownership is 42.09%. The most recent insider transaction that took place on Dec 17 ’24, was worth 1,167,100. In this transaction CHIEF MEDICAL OFFICER of this company sold 100,000 shares at a rate of $11.67, taking the stock ownership to the 1,098,499 shares. Before that another transaction happened on Dec 17 ’24, when Company’s PRESIDENT AND CEO sold 100,000 for $11.67, making the entire transaction worth $1,167,100. This insider now owns 1,098,499 shares in total.
ARS Pharmaceuticals Inc (SPRY) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.19% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Check out the current performance indicators for ARS Pharmaceuticals Inc (SPRY). In the past quarter, the stock posted a quick ratio of 12.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 431.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.36 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Compared to the last year’s volume of 0.84 million, its volume of 1.54 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 26.29%. Additionally, its Average True Range was 0.84.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 26.08%, which indicates a significant increase from 20.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.92% in the past 14 days, which was lower than the 72.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.23, while its 200-day Moving Average is $11.46. Nevertheless, the first resistance level for the watch stands at $11.58 in the near term. At $11.74, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.02. If the price goes on to break the first support level at $11.13, it is likely to go to the next support level at $10.85. Now, if the price goes above the second support level, the third support stands at $10.69.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
There are currently 97,185K shares outstanding in the company with a market cap of 1.11 billion. Presently, the company’s annual sales total 30 K according to its annual income of -54,370 K. Last quarter, the company’s sales amounted to 2,070 K and its income totaled -19,130 K.
